Azurity Pharmaceuticals has announced a breakthrough in the treatment landscape for chronic myeloid leukemia (CML). The FDA has approved Danziten™, the first and only nilotinib formulation that... read more
Azurity Pharmaceuticals has announced a breakthrough in the treatment landscape for chronic myeloid leukemia (CML). The FDA has approved Danziten™, the first and only nilotinib formulation that... read more
New method can calculate transmission weeks in advance so public can better prepare for outbreaks
Using a novel forecasting approach that combines mathematics with artificial... read more
PharmaBlock (Stock code: 300725.SZSE), a global, fully integrated CRDMO with a focus on innovative chemistry and low-carbon manufacturing, is proud to announce that it has been awarded... read more
